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Background  and  purpose     Although  total  ankle  replacement 
(TAR)  is  a  recognized  procedure  for  treatment  of  the  painful 
arthritic  ankle,  the  best  choice  of  implant  and  the  long-term 
results are still unknown. We evaluated the survival of two TAR 
designs and factors associated with survival using data from the 
nationwide arthroplasty registry in Finland. 
Methods   573 primary TARs were performed during the period 
1982–2006  because  of  rheumatic,  arthritic,  or  posttraumatic 
ankle degeneration. We selected contemporary TAR designs that 
were each used in more than 40 operations, including the S.T.A.R. 
(n = 217) and AES (n = 298), to assess their respective survival 
rates. The mean age of the patients was 55 (17–86) years and 63% 
of operations were performed in women. Kaplan-Meier analysis 
and the Cox regression model were used for survival analysis. The 
effects of age, sex, diagnosis, and hospital volume were also stud-
ied.
Results   The annual incidence of TAR was 1.5 per 105 inhabit-
ants. The 5-year overall survivorship for the whole TAR cohort 
was 83% (95% CI: 81–86), which agrees with earlier reports. The 
most frequent reasons for revision were aseptic loosening of one 
or both of the prosthesis components (39%) and instability (39%). 
We  found  no  difference  in  survival  rate  between  the  S.T.A.R. 
and AES designs. Furthermore, age, sex, diagnosis, and hospital 
volume (< 10 and > 100 replacements in each of 17 hospitals) did 
not affect the TAR survival. 
Interpretation   Based on our findings, we cannot conclude that 
any prosthesis was superior to any other. A high number of tech-
nical errors in primary TARs suggests that this low-volume field 
of implant arthroplasty should be centralized to fewer units.

 
Total ankle replacement (TAR) is a rather infrequently per-
formed operation with a reported annual incidence of 0.7 per 
105 (Henricson et al 2007). Most TARs are implanted in end-
stage rheumatoid arthritis (RA) but the proportion of other 
diagnoses has been increasing (Stengel et al. 2005, Fevang et 
al. 2007, Henricson et al 2007, Wood et al. 2008). Specialized 
centers have reported TAR 5-year survival rates of 70–93% 
(Anderson et al. 2003, Knecht et al. 2004, Spirt et al. 2004, 
Doets et al. 2006, San Giovanni et al. 2006, Wood et al. 2008, 
2009) using second- and third-generation implants. The Nor-
wegian and Swedish national registries have reported slightly 
inferior survival rates of 78–89% at 5 years and 62–72% at 10 
years (Fevang et al. 2007, Henricson et al. 2007).
We analyzed the survival of two TAR designs and the factors 
affecting survival at a national level by using the data from the 
Finnish Arthroplasty Register.
Patients and methods
Our study was based on information recorded in the Finn-
ish Arthroplasty Register (Puolakka et al. 2001) relating to 
patients who underwent TAR between 1982 and 2006. The 
coverage of the Finnish Arthroplasty Register was analyzed 
in 1994–1995 by comparing its data with those of the dis-
charge registers of the participating hospitals; it was found 
to cover 90% of implantations and implant removals. Since 
1995, the data in the register have been compared with those 
of the hospital discharge registers every few years. Currently, 
over 95% of implantations are recorded. An English transla-
tion of the form used for data collection has been published 
elsewhere (Paavolainen et al. 1991). Revisions were linked to 
the primary operation using the unique personal identification 
number assigned to each resident of Finland.
There were data on 645 TARs, each of which have been 
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register. Of these 645 TARs, 573 (89%) were primary opera-
tions and 72 (11%) were revisions.
Inclusion criteria
In order to assess the survival of different TAR designs, we 
selected only those designs that had been used in more than 
40 operations during the study period (Havelin et al. 1995). 
In addition, only implants with a mean follow-up of more 
than 2 years and more than 20 patients at risk at 3 years were 
included. We included bilateral TARs as separate cases in the 
analysis since bias by this procedure is probably negligible 
(Robertsson and Ranstam 2003).
Type of prosthesis
To meet our inclusion criteria, the following implants were 
selected: LINK S.T.A.R. (Scandinavian Total Ankle Replace-
ment)  System  (Waldemar  Link,  Hamburg,  Germany)  and 
BIOMET  AES  (Ankle  Evolutive  System)  (manufactured 
by Transystème, Nîmes, France and distributed by Biomet, 
Valence, France). Both prostheses are third-generation mobile-
bearing designs. All the S.T.A.R. prostheses were uncemented, 
double-coated  versions.  All  the  AES  implants  were  unce-
mented, but the implant was changed by the manufacturer in 
2004—from single-coated to a porous double-coated version 
with monobloc tibial component (the earlier tibia was modu-
lar). Of the other implant designs in use in Finland at the end 
of 2006, the Hintegra (Newdeal, Lyon, France) was excluded 
due to an insufficient number of operations (11). The use of 
the earlier designs was infrequent, and the designs were dis-
continued in the late 1980s (Table 1). 515 primary TARs were 
included in the study.
Diagnosis
Half of the 515 TARs were performed due to rheumatoid arthri-
tis (RA) (n = 252, 49%). Other indications included posttrau-
matic (n = 111, 22%) and primary (n = 99, 19%) osteoarthritis, 
other arthritides (n = 9, 2%), and other diseases (n = 44, 8%). 
We analyzed the overall survival of TARs performed due to 
RA and compared it to the “other indications” group in order 
to assess the effect of underlying disease.
Hospitals
355 (69%) of the 515 TARs were performed in 1 founda-
tion-based hospital and 2 university hospitals, each of which 
performed more than 100 TARs during the period 1997–2006 
(group A). 4 more hospitals had performed 10–50 TARs (group 
B), and 10 other hospitals less than 10 operations (group C). 
We analyzed the overall survival of TARs performed in high-
volume hospitals (group A) and compared this to that of the 
2 low-volume hospital groups together (A vs. B and C) and 
separately (A vs. B vs. C) in order to assess the effect of hos-
pital volume.
Statistics
The endpoint for survival was defined as revision with either 
one component or the whole implant removed or exchanged. 
Kaplan-Meier survival data were used to construct the survival 
probabilities of implants at 1, 3, 5, and 7 years. Survival data 
obtained in the Kaplan-Meier analysis were compared by the 
log-rank test. The Cox multiple-regression model was used to 
study differences between groups and to adjust for potential 
confounding factors. In all models, the confounding factors 
were age and sex. The factors studied with the Cox model 
were TAR design and hospital type (high-volume hospitals vs. 
low-volume hospitals). All models included adjustment for 
differences in age and sex.
The Cox regression analyses provided estimates of survival 
probabilities and revision risk ratios (RR) for different fac-
tors. Estimates from the Cox analyses were used to construct 
adjusted survival curves at mean values of the risk factors. The 
Wald test was used to calculate p-values for data obtained from 
the  Cox  multiple-regression  analysis.  Differences  between 
groups were considered statistically significant if the p-values 
were less than 0.05 in a two-tailed test. We used the SPSS 
software version 17.0.
Results
Patient characteristics
463 (90%) of the primary TARs were unilateral, and in 26 
patients a 2-stage bilateral replacement was done. Of the 515 
TAR operations, 327 (63%) were performed in women. At the 
time of the operation, the mean age of the patients was 55 
(17–86) years. During the last 5 years, the mean annual inci-
dence of TAR was 1.5 (95% CI: 1.3–1.8) per 105 inhabitants 
(Figure 1).
Implants
Over the whole study period, 9 TAR designs were used but 
only 2 of them had more than 40 operations (Table 1). At the 
end of the study period (2005–2006), 3 TAR designs were still 
being used.
Table 1. Implants used for primary total ankle replacement in Fin-
land during the period 1980–2006
Brand of implant   n   Used during    Included
    years  in analysis
AES   298   2002–2006   yes
S.T.A.R.   217   1997–2006   yes
ICLH   32   1980–1987   no
Hintegra   11   2005–2006   no
Thompson-Parkridge- Richards   6   1980–1984   no
Oregon   4   1980–1985   no
RCM   3   1981–1984   no
Other   2   1980–1986   no
Total   573  116  Acta Orthopaedica 2010; 81 (1): 114–118
Disease-dependent survival
The Cox regression model (adjusted for age and sex) showed 
a similar risk of revision in all disease subgroups.
Design-dependent survival
We found no differences in survival rates between S.T.A.R. 
and AES TAR designs over the whole study period, using 
either  Kaplan-Meier  analysis  or  the  Cox  regression  model 
(with or without adjustment for age and sex) (Tables 2 and 3 
and Figures 2 and 3). The 5-year survivorship for the whole 
TAR cohort was 83% (95% CI: 81–86) using revision for any 
reason as endpoint, and 95% (95% CI: 92–92) using revision 
for aseptic loosening as endpoint.
Age- and sex-dependent survival
Age and sex did not have any statistically significant effect 
on survivorship in the Cox multiple regression models (unad-
justed and adjusted for implant design).
Hospital volume-dependent survival
Hospital  volume  did  not  have  any  statistically  significant 
effect on survivorship in the Cox multiple regression models 
(unadjusted and adjusted for implant design).
Revision operations
During  the  period  1997–2006,  59  revisions  were  reported 
(Table 4). Thus, the 7-year survivorship for the whole TAR 
cohort was 78% (95% CI: 71–85). The most common reasons 
for revision were aseptic loosening (39%, n = 23) and instabil-
ity (39%, n = 23). This was followed by primary malalignment 
of the prosthesis (8%, n = 5), infection (7%, n = 4), fracture of 
the meniscal implant (5%, n = 3), and periprosthetic fracture 
(2%, n = 1).
Figure 1. Number of ankle prostheses implanted per year in Finland 
during the period 1997–2006.
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Table 2. Ankle replacements related to diagnosis during the period 
1997–2006
   Rheumatoid   Other    All 
  arthritis  indications  indications
Mean follow-up time 
   in years (range)   3.4 (0.1–9.6)   2.9 (0.1–9.1)   3.2 (0.1–9.6)
Mean age at operation 
   (range)   53 (17–81)   56 (18–86)   55 (17–86)
% Women   78%   50%   63%
Total number of 
  TARs   252   263   515
  S.T.A.R.   128     89   217
  AES   124   174   298
No. of patients with 
   bilateral operations     18      8     26
Table 3. Survival rates and Cox-adjusted risk ratios for revision of S.T.A.R. and AES total ankle replacements during the period 1997–2006 
in Finland. The endpoint was defined as revision for any reason, and revision for aseptic loosening of one or both of the prosthesis com-
ponents
  A  B  C  D  E  F  G  H  I
Revision for any reason            
  S.T.A.R.   31 / 217   4.8 (0–9.6)   199    96 (94–99)   180  92 (88–96)   112  85 (80–90)   24   80 (73–88)   1.0   –
  AES   28 / 298   2.0 (0–4.7)   227    96 (93–98)   69  88 (84–93)   –   –   –   –   1.7 (0.9–3.0)   0 . 1                      
Aseptic loosening            
  S.T.A.R.     9 / 217   4.8 (0–9.6)   199  100 (99–100)   180  98 (97–100)   112  96 (93–99)   24   91 (84–98)   1.0   –
  AES     5 / 298   2.0 (0–4.7)   227  100 (99–100)   69  98 (97–100)   –   –   –   –   2.7 (0.7–10.9)   0.2
A  Implant design  
B  No. of revisions / no. of total operations.  
C Mean follow-up in years (range)  
D At risk at 1 year, 1-year survival (%) and (95% CI)
E  At risk at 3 years,  3-year survival (%) and (95% CI) 
F  At risk at 5 years, 5-year survival (%) and (95% CI) 
G At risk at 7 years, 7-year survival (%) and (95% CI) 
H Adjusted risk ratio from the Cox regression analysis (adjustment was made for age and sex) for revision (95% CI) 
I  p-valueActa Orthopaedica 2010; 81 (1): 114–118  117
Discussion
Our main finding was the relatively low survival of TAR, with 
only 83% of cases revision-free at 5 years. We found no differ-
ences in survival between different TAR designs or concepts. 
Age, sex, diagnosis, and hospital volume did not affect the 
TAR survival. The mean annual incidence of TAR was 1.5 per 
105, which is twice the reported incidence in Sweden (Hen-
ricson et al. 2007).
We acknowledge that our registry-based study has certain 
limitations. For example, we were not able to report any sub-
jective outcome measurements, e.g. ankle performance scores 
or disease-specific quality of life measurements. Moreover, no 
radiographic analyses were done. Furthermore, in rheumatoid 
patients, a registry-based study may have pitfalls in that some 
of the patients diagnosed with RA are actually affected by 
juvenile or other subtypes of chronic arthritis. Another impor-
tant issue, especially with an ankle register, is that a failed TAR 
is often converted to an arthrodesis. This may result in under-
reporting of failures despite instructions, because the implants 
used in ankle arthrodesis are not reported to the arthroplasty 
register and a small number of these conversions may be done 
by orthopedic surgeons who are not familiar with reporting to 
the register.
In studies based on the Swedish and Norwegian national 
registries, aseptic loosening has been the most frequent reason 
for revision (31–48%) (Fevang et al. 2007, Henricson et al. 
2007), results that are inferior to those of total hip and knee 
arthroplasty. Curiously, the survival rate reported here (95% 
using revision for aseptic loosening only as the endpoint) is 
similar to the survival of total knee arthroplasty (94–96%) 
(Furnes  et  al.  2002).  Considering  the  major  complications 
recently found with the AES implant as a result of osteoly-
sis (Koivu et al. 2009), the currently good survival rates may 
become worse within the foreseeable future.
Interestingly, the proportion of revisions done for instabil-
ity in primary TAR was notably high (39%) compared to the 
Swedish (16%) and Norwegian results (14%), which probably 
indicates a long learning curve for TAR. However, some of the 
primary TARs revised for instability may have been in accept-
able alignment and balance immediately after surgery. In these 
cases, a marked preoperative varus or valgus deformity may 
have been corrected but degenerated ligaments may have been 
insufficient to sustain the balance after full weight bearing, 
and components may have migrated during follow-up due to 
poor bone quality, especially in RA. The migrated prosthe-
sis components were found to be well-fixed in many of these 
cases at the time of revision.
Figure 3. Kaplan-Meier survival curves for 217 S.T.A.R. and 298 AES 
total ankle replacements (with a mean follow-up of 4.8 and 2.0 years, 
respectively). The endpoint was defined as revision for any reason. The 
difference between survival rates is not statistically significant (Log-
rank test; p = 0.08).
Figure 2. Kaplan-Meier survival curves for 217 S.T.A.R. and 298 AES 
total ankle replacements (with a mean follow-up of 4.8 and 2.0 years, 
respectively). The endpoint was defined as revision for aseptic loosen-
ing of one or both of the prosthesis components, and revision for any 
reason. The difference between survival rates for aseptic loosening of 
the 2 kinds of ankle replacements is not statistically significant (Log-
rank test; p = 0.2).
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Table 4. Reasons for 59 revisions in 217 S.T.A.R. and 298 AES total 
ankle  replacements  (with  a  mean  follow-up  time  of  4.8  and  2.0 
years, respectively)
   S.T.A.R.   AES   All
Aseptic loosening   16   7   23 
   tibia   10   2   –
   talus   3   5   –
   both   3   0   –
Infection   3  1   4 
Instability a   6   17   23 
Fracture of the meniscal implant   2   1   3 
Periprosthetic fracture   0   1   1 
Primary malalignment of the prosthesis   4   1   5 
Total   31   28   59 
a With or without dislocation of the meniscal implant.118  Acta Orthopaedica 2010; 81 (1): 114–118
It  is  commonly  believed  that  the  patient’s  age,  sex,  and 
diagnosis have an influence on implant survival in TAR. In 
the Swedish study, only lower age was associated with an 
increased risk of later revision, but similarly to the Norwegian 
study we did not find such an association. 
Jain et al. (2004) found a clear association between surgeon 
volume  and  outcome  in  patients  who  had  a  total  shoulder 
arthroplasty or hemiarthroplasty. We have previously found 
an  association  between  the  hospital  volume  and  failure  in 
total elbow arthroplasty (Skyttä et al. 2009), and several stud-
ies have associated both surgeon volume and hospital volume 
with implant failure in hip replacement (Solomon et al. 2002). 
Fevang et al. (2007) found similar survival after TAR regard-
less of the size of the hospital. Henricson et al. (2007) found 
better 5-year survival in surgeons who had preformed more 
than 40 TARs, when comparing their first 30 TARs with oper-
ations performed thereafter. In our study, we did not find any 
differences in TAR survival when comparing high-volume and 
low-volume institutions. There are two explanations for this 
finding. First of all, many of the low-volume institutions are 
private clinics, where the surgeon comes from a high-volume 
hospital to perform the operation. Secondly, as the number of 
TARs performed annually in Finland is low, few surgeons ever 
reach and maintain the level of skill at the top of the learning 
curve.
There was an obvious shift from the S.T.A.R. prosthesis to 
the AES prosthesis during 2002–2003. The main reasons for 
this are technical: surgical instrumentation for the S.T.A.R. 
prosthesis is more difficult to use and the lack of trial implants 
caused many ankle surgeons to switch to the AES (Table 4). 
Also, the prosthesis sizing may be more favorable with the 
AES, allowing proper anteroposterior coverage without excess 
malleolar resection. Furthermore, radiographic follow-up of 
the S.T.A.R. talar implant is more complicated than with the 
AES. 
Based on our findings, we cannot conclude that any pros-
thesis was superior to any other. A high number of compli-
cations in primary TARs were associated with balance and 
instability. These issues require a profound understanding of 
not only the ankle joint, but also the whole hindfoot. Based 
on earlier studies on low-volume joint replacement (Jain et 
al. 2004, Henricson et al. 2007, Skyttä et al. 2009), we sug-
gest that performance of TARs should be centralized. With the 
Finnish population of 5.3 million, a sufficient number of TAR 
units would be 2–3 with 2 surgeons operating together at each 
unit. Thus, each surgeon would operate or assist at at least 25 
TARs annually.
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